- AstraZeneca’s AZN drug Wainua failed its late-stage cardiovascular trial: in 1,432 patients over 140 weeks, adding Wainua to standard care showed no significant cut in CV deaths or recurrent events
- AstraZeneca, with Daiichi Sankyo, nears deal with UK regulator and NHS England on Enhertu price for HER2-low metastatic breast cancer to improve access across England, Wales and Northern Ireland
- AstraZeneca (AZN) and Daiichi Sankyo nearing UK pricing and reimbursement deal for their breast cancer drug; negotiations focus on finalizing terms with UK health authorities.
- AstraZeneca (AZN) partners with PureHealth and Abu Dhabi Health to open a Rare Diseases Centre in Abu Dhabi, focusing on diagnosis, lifelong care, treatment, research and real-world data generation.
TradingView
Key facts: Wainua fails CV trial; Enhertu nears UK price deal
- Sources
- TradingView
- Active symbols
- LSE:AZN
- Language
- English
AstraZeneca’s AZN drug Wainua failed its late-stage cardiovascular trial: in 1,432 patients over 140 weeks, adding Wainua to standard care showed no significant cut in CV deaths or